跳至主要内容
临床试验/JPRN-UMIN000006085
JPRN-UMIN000006085已完成2 期

A feasibility study of sequential Anthracycline-based regimen and Nab-Paclitaxel / Trastuzumab followed by Trastuzumab as postoperative adjuvant chemotherapy for Her2 positive breast cancer.(SBCCSG-22) - Anthracycline, Nab-Paclitaxel and Trastuzumab in the adjuvant therapy of HER-2 positive breast cancer.(SBCCSG-22)

Saitama Breast Cancer Clinical Study Group(SBCCSG)0 个研究点目标入组 30 人开始时间: 2011年8月1日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18years-old 至 70years-old(—)
性别
Female

入选标准

  • 未提供

排除标准

  • 1) Pregnant or lactation women. 2) History of other malignancies within the last 5 years. 3) History of bilateral breast cancer 4) History of serious allergy 5) Serious cardiac disfunction 6) Patients judged by the investigator to be unfit to be enrolled into the study.

研究者

发起方
Saitama Breast Cancer Clinical Study Group(SBCCSG)

相似试验

A feasibility study of sequential... | 临床试验